A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BKM120
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Novartis Pharmaceuticals|Dana-Farber Cancer Institute|Stand Up To Cancer